Cover image for Vol. 12 Issue 23

Editorial Board Chairs: Karl-Heinz Altmann, Antonello Mai, Rainer Metternich. Editor: David Peralta

Impact Factor: 3.225

ISI Journal Citation Reports © Ranking: 2016: 17/60 (Chemistry Medicinal); 73/257 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

January 12, 2013

VIP: Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

VIP: Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against TuberculosisLluís Ballell,* Robert H. Bates, Rob J. Young, Daniel Alvarez-Gomez, Emilio Alvarez-Ruiz, Vanessa Barroso, Delia Blanco, Benigno Crespo, Jaime Escribano, Rubén González, Sonia Lozano, Sophie Huss, Angel Santos-Villarejo, José Julio Martín-Plaza, Alfonso Mendoza, María Jose Rebollo-Lopez, Modesto Remuiñan-Blanco, José-Luis Lavandera, Esther Pérez-Herran, Francisco Javier Gamo-Benito, José Francisco García-Bustos, David Barros, Julia P. Castro, Nicholas Cammack

Opening doors in tuberculosis drug discovery: Building on an open-innovation strategy that began with publication of the antimalarial set, researchers at the GlaxoSmithKline Tres Cantos Medicines Development Campus (TCMDC) have now screened the company's entire pharmaceutical library of more than two million compounds to find any that can inhibit tuberculosis (TB). In their Full Paper, Lluís Ballell and colleagues describe the structure, antitubercular properties, and drug-like profile of 177 promising “hits” that the company will make available to researchers wishing to investigate further. Ballell's team envisages that the release of GSK and other proprietary anti-TB screening sets should enable the creation of a virtual community of scientists engaged in drug discovery for neglected diseases.

Received September 19, 2012; published online January 10, 2013, DOI: 10.1002/cmdc.201200428.

Your Comment...

[Browse more news]